InnoCare licensing deal flops due to lack of upfront cash
The Chinese biotech agreed to sell some of the rights to its flagship drug for a sum that could exceed $2 billion but investors were unhappy with the fine print…
Recent Articles
InnoCare licensing deal flops due to lack of upfront cash
9969.HK
688428.SHG
